Evidence map›Paper›PMID 35160189›Full record

ArticleJournal of clinical medicine2022

Sociodemographic and Illness-Related Indicators to Predict the Status of Neuromyelitis Optica Spectrum Disorder (NMOSD) Five Years after Disease Onset.

Dena Sadeghi-Bahmani, Mahdi Barzegar, Omid Mirmosayyeb, Saeed Vaheb, Nasim Nehzat, Vahid Shaygannejad, Serge Brand

Open access · goldAbstract read
In one paragraph

Article in Journal of clinical medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 3 countries.

Dena Sadeghi-BahmaniDepartment of Psychology, University of Stanford, Stanford, CA 94305, USA.ORCID 0000-0002-1301-5522
Mahdi BarzegarDepartment of Neurology, School of Medicine, Isfahan University of Medical Sciences, Isfahan 8174673461, Iran.ORCID 0000-0002-6578-0250
Omid MirmosayyebDepartment of Neurology, School of Medicine, Isfahan University of Medical Sciences, Isfahan 8174673461, Iran.ORCID 0000-0002-3756-2985
Saeed VahebIsfahan Neurosciences Research Center, Isfahan University of Medical Sciences, Isfahan 8174673461, Iran.ORCID 0000-0001-5738-7419
Nasim NehzatIsfahan Neurosciences Research Center, Isfahan University of Medical Sciences, Isfahan 8174673461, Iran.
Vahid ShaygannejadDepartment of Neurology, School of Medicine, Isfahan University of Medical Sciences, Isfahan 8174673461, Iran.
Serge BrandPsychiatric Clinics, Center for Affective, Stress and Sleep Disorders, University of Basel, 4002 Basel, Switzerland.ORCID 0000-0003-2175-2765
Isfahan University of Medical Sciences · IRUniversity of Basel · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundNeuromyelitis Optica Spectrum Disorder (NMOSD) is an autoimmune demyelinating disease of the central nervous system. Currently, no factors have been identified to predict the long-term course of NMOSD. To counter this, we analyzed data of 58 individuals with NMOSD at disease onset and about five years later.

methodsMedical records of 58 individuals with NMOSD (mean age: 31.13 years at disease onset; 86.2% female) were retrospectively analyzed. At baseline, a thorough medical and disease-related examination was performed; the same examination was repeated about five years later at follow-up, including treatment-related information. Mean outcome measure was the difference in EDSS (Expanded Disease Severity Scale) scores between baseline and follow-up.

resultsMean disease duration was 4.67 years. Based on the differences of the EDSS scores between baseline and follow-up, participants were categorized as improving (

conclusionsAmong a smaller sample of individuals with NMOSD followed-up about five years later, individuals deteriorating over time reported a higher progression index, while the annualized relapse rate was unrelated to the progress of disease. Overall, it appears that the course of NMOSD over a time lapse of about five years after disease onset is highly individualized. Accordingly, treatment regimen demands a highly individually tailored approach.

Indexed as

EDSSlong-term courseneuromyelitis optica spectrum disorderpredictors

Identifiers

PMID35160189
PMCPMC8836947
OpenAlexW4210637830

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.